<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Posttraumatic stress disorder in adults: Treatment overview
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Posttraumatic stress disorder in adults: Treatment overview
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Posttraumatic stress disorder in adults: Treatment overview
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Murray B Stein, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter P Roy-Byrne, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Friedman, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 02, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3296388397">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Posttraumatic stress disorder (PTSD) is a severe, often chronic, and disabling disorder, which develops in some persons following exposure to a traumatic event involving actual or threatened injury to themselves or others. PTSD is characterized by intrusive thoughts, nightmares, and flashbacks of past traumatic events, avoidance of reminders of trauma, hypervigilance, and sleep disturbance, all of which lead to considerable social, occupational, and interpersonal dysfunction.
        </p>
        <p>
         Effective treatments for PTSD include psychotherapies and medications. However, some patients are unwilling to pursue treatment, and a substantial proportion of patients who do seek treatment have symptoms resistant to treatment. It is often necessary to switch or combine treatments to achieve a satisfactory therapeutic response.
        </p>
        <p>
         This topic describes our approach to selecting treatment for PTSD in adults. This is also summarized in an algorithm  (
         <a class="graphic graphic_algorithm graphicRef118826" href="/z/d/graphic/118826.html" rel="external">
          algorithm 1
         </a>
         ). The epidemiology, pathophysiology, clinical manifestations, assessment, diagnosis, psychotherapy, and pharmacotherapy for PTSD in adults are reviewed separately. Acute stress disorder and prevention of the development of PTSD, dissociative aspects of PTSD, and PTSD in children and adolescents are also reviewed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/500.html" rel="external">
          "Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14634.html" rel="external">
          "Posttraumatic stress disorder in adults: Psychotherapy and psychosocial interventions"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14616.html" rel="external">
          "Acute stress disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14699.html" rel="external">
          "Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, assessment, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16867.html" rel="external">
          "Acute stress disorder in adults: Treatment overview"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14345.html" rel="external">
          "Posttraumatic stress disorder in children and adolescents: Epidemiology, clinical features, assessment, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/104096.html" rel="external">
          "Posttraumatic stress disorder in children and adolescents: Treatment overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H449522128">
         <span class="h1">
          INITIATING TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We prefer to begin treatment for posttraumatic stress disorder (PTSD) as soon as possible after the diagnosis is made. Early treatment of PTSD may prevent chronicity; however, more empirical data to support this are needed particularly for pharmacotherapeutic treatment [
         <a href="#rid1">
          1
         </a>
         ]. Additionally, supportive interventions such as psychoeducation and case management appear to be helpful in acutely traumatized individuals [
         <a href="#rid1">
          1
         </a>
         ]. While the diagnosis of PTSD is made after persistence of symptoms for at least four weeks following the trauma, most individuals present for treatment many months, or years, later.
        </p>
        <p class="headingAnchor" id="H3702880393">
         <span class="h2">
          Establishing treatment goals
         </span>
         <span class="headingEndMark">
          —
         </span>
         We work with the patient and with permission, involve their chosen support (eg, family member, partner) to establish treatment goals. We review the goals of treatment at each visit through direct questioning during symptom review. (See
         <a class="medical medical_review" href="/z/d/html/500.html" rel="external">
          "Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis", section on 'Cardinal features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/500.html" rel="external">
          "Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis", section on 'Assessment'
         </a>
         .)
        </p>
        <p>
         Specific treatment goals may vary between patients; however, for all individuals our goals include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintain the safety of the patient and others – We do this through assessments of suicidality and homicidality at regularly scheduled visits. (See
         <a class="medical medical_review" href="/z/d/html/1708.html" rel="external">
          "Suicidal ideation and behavior in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduce symptoms of distress related to intrusive re-experiencing – Unwanted intrusive memories of the traumatic event vary widely from occasional unwanted thoughts to frequent nightmares or flashbacks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduce hyperarousal – These can include symptoms such as insomnia, anger, irritability, and trouble concentrating and can be very distressing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduce avoidant behaviors – Avoidance of stimuli associated with the traumatic event may lead to behavior changes that affect psychosocial functioning.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lessen the risk of relapse of symptoms and diminish anxiety related to fear of recurrence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Address related comorbidities that may be present, for example, substance use disorder (SUD) or mood dysregulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improve adaptive and psychosocial functioning through psychotherapy often combined with pharmacologic management.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4224074612">
         <span class="h2">
          Trauma-focused psychotherapy as preferred treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most adults diagnosed with PTSD, we suggest first-line treatment with a trauma-focused psychotherapy that includes exposure rather than other types of therapy, or medication (eg, selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor [SNRI]).
        </p>
        <p>
         However, in individuals with comorbid disorders (eg, depression, psychosis) that affect the person’s ability to work in trauma-focused therapy (eg, concentration, motivation), we treat with pharmacologic management until the individual’s symptoms are stable, then add psychotherapy. (See
         <a class="local">
          'Serotonin reuptake inhibitors as alternative first-line or adjunctive treatment'
         </a>
         below.)
        </p>
        <p>
         Clinical trials and meta-analysis have found trauma-focused therapies including trauma-focused cognitive-behavioral therapy (CBT; eg, cognitive processing therapy), exposure-based therapy (eg, prolonged and written exposure), and eye movement desensitization and reprocessing therapy to be effective in the treatment of PTSD in adults [
         <a href="#rid2">
          2-5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14634.html" rel="external">
          "Posttraumatic stress disorder in adults: Psychotherapy and psychosocial interventions", section on 'Trauma-focused therapy as first-line treatment'
         </a>
         .)
        </p>
        <p>
         The choice of trauma-focused therapy is one of shared decision making and is based on patient presentation, patient preference, and therapist expertise. Choosing among trauma-focused therapies for individuals with PTSD is discussed further elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14634.html" rel="external">
          "Posttraumatic stress disorder in adults: Psychotherapy and psychosocial interventions", section on 'Choosing among trauma-focused therapies'
         </a>
         .)
        </p>
        <p>
         Trauma-focused psychotherapies are the most extensively studied therapy for the treatment of PTSD [
         <a href="#rid2">
          2-4,6
         </a>
         ].
        </p>
        <p>
         In a meta-analysis of 14 trials including 649 individuals with PTSD, individuals treated with trauma-focused CBT or exposure therapy showed greater improvement in clinician-rated severity of PTSD symptoms (eg, Clinician-Administered PTSD Scale [CAPS] than individuals in wait list or usual care group at treatment end [standardized mean difference -1.4, 95% CI -1.89 to 0.91]) [
         <a href="#rid2">
          2
         </a>
         ]. Furthermore, subgroup analysis (nine trials, n = 428) report individuals treated with exposure showed greater improvement on self-report measures (eg, Impact of Event Scale) of PTSD symptoms at treatment end than individuals in wait list or control group (standardized mean difference -1.68, 95% CI -2.14 to -1.22) [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14634.html" rel="external">
          "Posttraumatic stress disorder in adults: Psychotherapy and psychosocial interventions", section on 'Trauma-focused therapy as first-line treatment'
         </a>
         .)
        </p>
        <p>
         Comparative clinical trials suggest that using monotherapy with SSRIs or trauma-focused therapy with exposure, are largely comparably effective for PTSD, with some advantage to psychotherapy and that the choice between the two should be based on patient preference [
         <a href="#rid7">
          7-9
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial including 200 individuals with PTSD, participants were first randomized either to treatment of choice (
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         or prolonged exposure) or randomized treatment assignment. Those assigned to randomized assignment were then further randomized to prolonged exposure versus treatment with sertraline [
         <a href="#rid7">
          7
         </a>
         ]. Efficacy of prolonged exposure and sertraline was, overall, equivalent across a range of outcomes, though some outcomes did favor prolonged exposure. There was a slight advantage (possibly mediated, in part, by better adherence) for patients who were randomized to their treatment of choice (irrespective of whether that treatment was prolonged exposure or sertraline), pointing to the importance of attending to patient preference in treatment selection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial including 207 patients with PTSD, participants were randomly assigned to receive
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         plus enhanced medication management, prolonged exposure therapy plus placebo, or prolonged exposure therapy plus sertraline and followed for 24 weeks [
         <a href="#rid8">
          8
         </a>
         ]. All groups experienced reduced PTSD symptoms, but did not differ in the magnitude of symptom reduction.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3939778704">
         <span class="h2">
          Serotonin reuptake inhibitors as alternative first-line or adjunctive treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         In individuals with comorbid disorders such as depression, we prefer to begin treatment with pharmacologic management with a serotonin reuptake inhibitor (SSRIs or SNRIs). This is particularly true in individuals with depression who may have low motivation or poor concentration.
        </p>
        <p>
         Our preference is to start with an SSRI such as
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         or
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         , rather than an SNRI such as
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         , as there are more studies investigating SSRIs. However, SNRIs are a reasonable alternative option.
        </p>
        <p>
         When these symptoms are less problematic (eg, they no longer interfere with the individuals ability to work in therapy), we begin trauma-focused therapy. (See
         <a class="local">
          'Trauma-focused psychotherapy as preferred treatment'
         </a>
         above.)
        </p>
        <p>
         Additionally, in individuals who prefer pharmacologic management to trauma-focused therapy we begin with pharmacotherapy.
        </p>
        <p class="headingAnchor" id="H2299786548">
         <span class="h3">
          Administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serotonin reuptake inhibitors (SSRIs and SNRIs) are typically started at the low end of their therapeutic range and titrated up gradually until response is achieved. Usual starting doses, low starting doses, and therapeutic dose ranges for commonly used are shown in a table  (
         <a class="graphic graphic_table graphicRef55682" href="/z/d/graphic/55682.html" rel="external">
          table 1
         </a>
         ). Although there is not clear evidence of a dose-response relationship for serotonin reuptake inhibitors in PTSD, it is common practice to push the dose to the very high end of the therapeutic range (to the extent that this is tolerated by the patient) before concluding that a therapeutic trial has failed. We consider a therapeutic trial with a serotonin reuptake inhibitor to be a minimum of six to eight weeks at maximally tolerated dose within the therapeutic range, before concluding that the medication has failed.
        </p>
        <p>
         As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          Paroxetine
         </a>
         can be started at 20 mg/day orally. If minimal or no clinical response is seen after three to four weeks, we typically increase the dose in 10 to 20 mg/day increments with at least two weeks between dosing increases, up to 60 mg/day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          Sertraline
         </a>
         can be started at 25 or 50 mg/day orally. If minimal or no clinical response is seen after three to four weeks, we typically increase doses in 25 to 50 mg/day increments with at least two weeks between dosing increases, up to 250 mg/day.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4255991048">
         <span class="h3">
          Efficacy of serotonin reuptake inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical trials have found serotonin reuptake inhibitors (SSRIs and SNRIs) to reduce PTSD symptoms compared with placebo [
         <a href="#rid10">
          10-13
         </a>
         ]. Clinical trials have not compared the efficacy of different medications for PTSD.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SSRIs
         </strong>
         – In a meta-analysis of 12 trials [
         <a href="#rid10">
          10
         </a>
         ] including 1909 individuals with PTSD, treatment with SSRIs led to a greater decline on the Clinician Administered PTSD Symptoms Scale, a structured interview for PTSD, than treatment with placebo (mean difference -5.6, 95% CI -8.6 to -2.6). Furthermore, indirect comparisons showed greater improvement on CAPS score with SSRIs than other medications (eg,
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SNRIs
         </strong>
         – Although there are fewer studies assessing the efficacy of SNRIs for PTSD compared with SSRIs, two randomized trials found
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         extended-release (ER) to be effective in reducing PTSD symptoms compared with placebo [
         <a href="#rid12">
          12,13
         </a>
         ]. As an example, 329 adults with PTSD were randomly assigned to receive venlafaxine ER or placebo for 24 weeks. Patients receiving venlafaxine ER were more likely to experience remission of PTSD symptoms compared with patients receiving placebo (50.9 versus 37.5 percent) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Response to pharmacologic treatment of PTSD varies greatly with few robust individual predictors of response available [
         <a href="#rid14">
          14,15
         </a>
         ]. Symptoms associated with PTSD, such as sleep disturbance, can be particularly difficult to treat, and are among the symptoms that result in the use of polypharmacy that is common in the treatment of PTSD [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p>
         Side effects of SSRIs and SNRIs are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Side effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1706.html" rel="external">
          "Sexual dysfunction caused by selective serotonin reuptake inhibitors (SSRIs): Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2343422346">
         <span class="h2">
          Additional considerations for specific populations or symptoms
         </span>
        </p>
        <p class="headingAnchor" id="H1048110549">
         <span class="h3">
          Substance use disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         We treat individuals with PTSD and an active SUD with a hybrid approach known as COPE (Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure) [
         <a href="#rid18">
          18-20
         </a>
         ]. Current substance use does not necessarily require delay of psychotherapy for PTSD. Discussion of concurrent treatment for PTSD and SUD may be found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14634.html" rel="external">
          "Posttraumatic stress disorder in adults: Psychotherapy and psychosocial interventions", section on 'Comorbid substance use disorder'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16753.html" rel="external">
          "Substance use disorders: Psychosocial management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1672447513">
         <span class="h3">
          Borderline personality disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         We treat individuals with co-occurring PTSD and borderline personality disorder with a modified treatment that combines prolonged exposure and dialectical behavior therapy. This is particularly useful if chronic suicidality and self-harm behaviors are prominent [
         <a href="#rid21">
          21
         </a>
         ]. Further discussion of the treatment of comorbid borderline personality disorder and PTSD may be found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14634.html" rel="external">
          "Posttraumatic stress disorder in adults: Psychotherapy and psychosocial interventions", section on 'Comorbid personality disorders'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6618.html" rel="external">
          "Borderline personality disorder: Psychotherapy", section on 'Dialectical behavior therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H223332730">
         <span class="h3">
          Comorbid traumatic brain injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hybrid psychotherapeutic approaches may offer additional improvements over standard therapy in the treatment of PTSD with comorbid moderate to severe traumatic brain injury (TBI) in military personnel returning from combat [
         <a href="#rid22">
          22
         </a>
         ]. For example, in an individual with PTSD and comorbid moderate to severe TBI, our preference is to use a hybrid approach that offers cognitive processing therapy with compensatory cognitive training. Most patients with mild TBIs do well with evidence-based approaches to PTSD without the requirement for the modification of those approaches. Further discussion of treatment of combined PTSD and TBI is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14634.html" rel="external">
          "Posttraumatic stress disorder in adults: Psychotherapy and psychosocial interventions", section on 'Comorbid TBI'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H278541256">
         <span class="h3">
          Prominent sleep disturbance or nightmares
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest treatment with
         <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">
          prazosin
         </a>
         for individuals with PTSD who experience significant sleep disturbance, most typically nightmares. In our clinical experience, prazosin appears to reduce overall PTSD symptoms, nightmares, and sleep disturbance in approximately 50 percent of patients with PTSD.
        </p>
        <p class="headingAnchor" id="H4290598738">
         <span class="h4">
          Alpha-adrenergic receptor blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         We typically use
         <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">
          prazosin
         </a>
         as an augmenting agent for individuals being treated with serotonin reuptake inhibitors (SSRI or SNRI); however, in some cases it is given as monotherapy or combined with trauma-focused therapy.
        </p>
        <p>
         Our preference is to start
         <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">
          prazosin
         </a>
         at 1 mg 30 to 60 minutes before bedtime and gradually increase to 3 to 15 mg over several months. We are cautious in treating individuals with hypotension (eg, due to being on other medications). Sudden discontinuation of prazosin must be avoided, as this can result in rebound hypertension.
        </p>
        <p>
         Clinical trials of
         <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">
          prazosin
         </a>
         for sleep disruption in PTSD have found mixed results [
         <a href="#rid23">
          23-25
         </a>
         ]. Possible reasons for the discrepancies include methodologic differences and heterogeneity in patient populations [
         <a href="#rid26">
          26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of six randomized clinical trials including 240 subjects (mostly military veterans or active-duty service members) with PTSD showed moderate to large effects of
         <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">
          prazosin
         </a>
         in reducing overall PTSD symptoms and nightmares and improving sleep quality [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a trial involving 67 active-duty United States Army personnel with PTSD returning from combat deployments from Iraq or Afghanistan, subjects were randomly assigned to treatment with
         <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">
          prazosin
         </a>
         versus placebo [
         <a href="#rid25">
          25
         </a>
         ]. Prazosin was superior to placebo in reducing nightmares, improving overall sleep quality, and improving overall clinical symptoms. The study was stopped early because of the early benefit observed with prazosin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent randomized trial in 304 veterans with PTSD failed to show benefits of
         <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">
          prazosin
         </a>
         compared with placebo in alleviating distressing dreams or improving sleep quality [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Further research is needed to identify whether specific subgroups of patients with PTSD are uniquely responsive to
         <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">
          prazosin
         </a>
         .
        </p>
        <p class="headingAnchor" id="H2453819008">
         <span class="h3">
          Psychosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In individuals with PTSD who have prominent psychotic symptoms we typically begin treatment with an SSRI and augment with a second-generation antipsychotic (SGA) medication [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H59829880">
         <span class="h4">
          Second-generation antipsychotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our preference is to treat individuals with prominent psychosis in the context of PTSD with an SGA. For example, if we are augmenting an SSRI with
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , we would begin with 0.5 mg orally at night. After one week we increase in weekly increments of 0.5 mg or 1 mg increments to a maximum of 4 mg/day. An alternative option is
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         which we would start at 25 mg orally at night and increase one week later if the response is inadequate. We titrate weekly in 50 mg increments up to 800 mg/day.
        </p>
        <p>
         If no clinical benefit is seen after two to three weeks of treatment at the maximal tolerated dose, we gradually discontinue the medication to lessen the risk of side effects.
        </p>
        <p>
         Randomized clinical trials provide some evidence of efficacy for SGAs in PTSD as monotherapy or augmenting serotonin reuptake inhibitors [
         <a href="#rid28">
          28-34
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized clinical trial 80 United States military veterans with chronic PTSD were treated with
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         versus placebo monotherapy [
         <a href="#rid28">
          28
         </a>
         ]. Quetiapine was started at 25 mg/day and increased to an average of 258 mg/day (range, 50 to 800 mg/day). After 12 weeks, mean reductions in CAPS total score were greater among the quetiapine-treated group than among those in the placebo group (mean change 21.5 versus 4.9, respectively). Additionally, subscores of hyperarousal and re-experiencing were greater for quetiapine-treated group than the placebo-treated group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A large trial involving SGA augmentation randomly assigned 247 United States military veterans who responded inadequately to two or more trials with an SSRI or SNRI to receive adjunctive
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         (up to 4 mg once daily) or placebo [
         <a href="#rid29">
          29
         </a>
         ]. Patients continued to receive other medication and psychosocial interventions for PTSD. After six months, no meaningful difference was seen in overall CAPS score (the primary outcome) compared with placebo, or in symptoms of anxiety, depression, or quality of life. Risperidone led to small, mean reductions in re-experiencing and hyperarousal symptoms. Participants receiving risperidone were more likely to experience weight gain, fatigue, somnolence, and hypersalivation compared with patients receiving placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other, smaller trials showed mixed results [
         <a href="#rid31">
          31,32,34
         </a>
         ]. Most of the patients in these studies were treated for combat-related PTSD; it is not clear whether the results are generalizable to the civilian population.
        </p>
        <p>
        </p>
        <p>
         Side effects, including weight gain and other metabolic abnormalities, make SGAs a less desirable option than serotonin reuptake inhibitors (SSRI or SNRI). Side effects of SGAs are shown in a table  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 2
         </a>
         ) and reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4160088357">
         <span class="h1">
          DURATION OF TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We continue medications that are effective for posttraumatic stress disorder (PTSD) for at least six months to one year in order prevent relapse or recurrence. A clinical trial randomly assigned 96 patients with PTSD who had completed 12 weeks of acute treatment with
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         to either 28 weeks of maintenance treatment with sertraline or to placebo. Patients who continued sertraline were less likely to relapse than patients receiving placebo (5 versus 26 percent) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Additionally, in individuals that respond favorably to psychotherapy with an evidence-based treatment for PTSD, we find that treatment gains are generally maintained [
         <a href="#rid36">
          36
         </a>
         ], with studies suggesting continued maintenance for 12 months [
         <a href="#rid37">
          37
         </a>
         ] but even more enduring outcomes likely for many patients.
        </p>
        <p class="headingAnchor" id="H3830151258">
         <span class="h1">
          MANAGEMENT OF SUBOPTIMAL RESPONSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our preference for psychotherapy, medication, or their combination in patients who experience a suboptimal (eg, poor or partial response) to initial treatment is made on the basis of treatment availability and/or patient preference. There are no clinical trials comparing medication with psychotherapy in posttraumatic stress disorder (PTSD) patients who do not respond to initial treatment.
        </p>
        <p>
         We assess for and address underlying or untreated psychiatric comorbidities in individuals that have a suboptimal (poor or partial response) to a therapeutic trial of medication (eg, eight weeks at therapeutic dose) or psychotherapy (eg, eight sessions, acceptable engagement in treatment, and adherence to treatment recommendations).
        </p>
        <p>
         Our preference for subsequent treatment is described below.
        </p>
        <p class="headingAnchor" id="H852308475">
         <span class="h2">
          Individuals who prefer psychotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals who prefer psychotherapy, our choices for treatment of suboptimal response to initial psychotherapy are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For poor response to initial psychotherapy, our preference is to switch to another trauma-focused therapy (eg, cognitive processing therapy).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For partial response to initial psychotherapy, our preference is to augment with another trauma-focused therapy (eg, trauma processing therapy).
        </p>
        <p>
        </p>
        <p>
         We choose subsequent psychotherapy based on the clinical presentation. As an example, if a patient is not willing or able to engage emotionally with the trauma memory and reminders, we change from exposure therapy to a combined cognitive therapy/exposure therapy.
        </p>
        <p>
         We often use assessment tools such as the Emory Treatment Resistance Interview for PTSD (E-TRIP) to help inform subsequent treatment decisions. The E-TRIP includes clinician-administered questions used to assess the adequacy and benefit derived from past treatment trials [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14634.html" rel="external">
          "Posttraumatic stress disorder in adults: Psychotherapy and psychosocial interventions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3208747074">
         <span class="h2">
          Individuals who prefer medication
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals preferring medication management, our choices after suboptimal response to initial treatment (with psychotherapy or pharmacotherapy), are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals with poor response to trauma-focused therapy our preference is to discontinue the therapy and switch to pharmacologic management with a selective serotonin reuptake inhibitor (SSRI).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals with poor response to initial medication management our choice is to switch to another SSRI. A trial of a serotonin-norepinephrine reuptake inhibitor (SNRI) is an acceptable option; however, SNRIs have been less extensively studied than SSRIs in the treatment of PTSD [
         <a href="#rid10">
          10,12,13
         </a>
         ]. We typically taper the first medication over two weeks while titrating the second one at the same time. While directly switching to a new SSRI at equivalent dose of the current SSRI is typically well tolerated, it is less preferred.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals who have failed to respond to two prior serotonin reuptake inhibitors (SSRI or SNRI) our preference is to treat with a second-generation antipsychotic (SGA) medication. (See
         <a class="local">
          'For individuals refractory to two or more serotonin reuptake inhibitors'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1045558410">
         <span class="h2">
          Individuals agreeable to combined modalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our clinical experience, augmentation of psychotherapy with an SSRI (or augmentation of an SSRI with psychotherapy) may be helpful for some. However, clinical trials have provided little direct evidence supporting greater improvement with the combination of cognitive-behavioral therapy and an SSRI/SNRI than either modality alone [
         <a href="#rid8">
          8,9,39-41
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eighty-eight patients with PTSD who were initially treated with
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         for 10 weeks and did not achieve a full response [
         <a href="#rid40">
          40
         </a>
         ] were randomly assigned to continue to receive sertraline alone or sertraline augmented with prolonged exposure for an additional five weeks. No difference in PTSD symptom reduction was seen between the two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seventy-eight patients with PTSD who were initially treated with eight sessions of prolonged exposure and experienced a partial response [
         <a href="#rid41">
          41
         </a>
         ] were randomly assigned to continued prolonged exposure with either controlled-release
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         or placebo. No difference was seen between the two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two hundred twenty-three patients with combat-related PTSD were randomized to receive up to 13 sessions of prolonged exposure plus placebo pills,
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         with enhanced medication management, or the combination of prolonged exposure and sertraline, with outcomes assessed by blinded raters at 24 weeks. No difference in change in PTSD symptoms or symptom severity at 24 weeks was found between sertraline plus enhanced medication management, prolonged exposure therapy plus placebo, and prolonged exposure therapy plus sertraline [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The administration, dosing, and side effects of serotonin reuptake inhibitors are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Side effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1706.html" rel="external">
          "Sexual dysfunction caused by selective serotonin reuptake inhibitors (SSRIs): Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1225956552">
         <span class="h2">
          For individuals refractory to two or more serotonin reuptake inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals preferring medication management who have not adequately responded to two or more trials of serotonin reuptake inhibitors (SSRI or SNRI) our preference is treatment with an SGA.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals with a partial response to serotonin reuptake inhibitor treatment we prefer to augment with
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         or
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals with minimal to no response to serotonin reuptake inhibitor treatment we use
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         or
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         monotherapy.
        </p>
        <p>
        </p>
        <p>
         Randomized trials provide some evidence of efficacy for SGAs in the treatment of PTSD as monotherapy [
         <a href="#rid28">
          28-30
         </a>
         ] or as augmentation [
         <a href="#rid31">
          31,32
         </a>
         ]. However, the side effect burden including weight gain and other metabolic abnormalities make SGAs a less desirable option than serotonin reuptake inhibitors. Side effects of SGAs are shown on the table  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Based upon the absence of other medications proven to be effective and our clinical experience that some patients appear to benefit from SGAs, they are an option for patients failing previously suggested treatment. (See
         <a class="local">
          'Second-generation antipsychotics'
         </a>
         above.)
        </p>
        <p>
         Administration and monitoring of individuals on SGAs may be found elsewhere. (See
         <a class="local">
          'Second-generation antipsychotics'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2884051366">
         <span class="h1">
          MEDICATIONS WITH LIMITED SUPPORTING EVIDENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not recommend the following agents due to limited evidence supporting their use in the treatment of posttraumatic stress disorder (PTSD).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benzodiazepines
         </strong>
         – Based on the absence of clear benefit and the possibility of worsening PTSD, we suggest not using benzodiazepines to treat patients with PTSD. Benzodiazepines have not been studied in adequately powered randomized clinical trials in PTSD, yet they are frequently used to treat symptoms of anxiety and hyperarousal [
         <a href="#rid16">
          16,17
         </a>
         ]. Some data suggest that benzodiazepines may impair the therapeutic effects of treatments, such as exposure therapy that rely on extinction learning [
         <a href="#rid42">
          42
         </a>
         ], but further study is needed to confirm this adverse effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additionally, given the high prevalence of comorbid substance use disorder (SUD) in patients with PTSD, we avoid using benzodiazepines in patients with an active SUD or a history of a benzodiazepine use disorder or alcohol use disorder. (See
         <a class="medical medical_review" href="/z/d/html/500.html" rel="external">
          "Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis", section on 'Co-occurring conditions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We monitor all patients prescribed benzodiazepines for PTSD for signs of misuse or abuse. (See
         <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">
          "Prescription drug misuse: Epidemiology, prevention, identification, and management", section on 'Sedatives-hypnotics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Beta-adrenergic blocking agents (eg,
         </strong>
         <strong>
          propranolol
         </strong>
         <strong>
          )
         </strong>
         – Although early reports proposed a potential use for beta-adrenergic blockers such as
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         in the early prevention or subsequent treatment of PTSD, subsequent studies have not supported this claim, and further research is needed [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mood stabilizers
         </strong>
         – Anticonvulsant medications with mood-stabilizing properties in other psychiatric disorders have insufficiently tested in clinical trials for their ability to reduce PTSD symptoms. Few adequately powered, randomized trials have been conducted, and findings have been mostly negative [
         <a href="#rid14">
          14,44-49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ketamine
         </strong>
         –
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         is an N-methyl-D-aspartic acid antagonist used as an anesthetic and is an emerging treatment for depression and PTSD. Based on clinical trials, treatment with ketamine combined with psychotherapy appears to reduce PTSD symptoms [
         <a href="#rid50">
          50-52
         </a>
         ]. In a meta-analysis of trials, 34 subjects with PTSD treated with a combination of ketamine infusion (various protocols) and psychotherapy for PTSD (psychotherapy protocols included 10 weeks Trauma Interventions Using Mindfulness-Based Extinction and Reconsolidation of Memories [TIMBER] therapy, 10 weekly sessions of prolonged exposure therapy, 5 daily sessions exposure therapy) showed greater improvement on PTSD symptoms than those treated psychotherapy and placebo [
         <a href="#rid52">
          52
         </a>
         ]. Improvements are reported on the Clinician-Administered PTSD scale (standardized mean difference -7.26, 95% CI -12.28 to -2.35) and the PTSD checklist (standardized mean difference -5.17, 95% CI -7.99 to -2.35). Further investigation of the potential of ketamine-assisted psychotherapy for PTSD are warranted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cannabis and synthetic cannabinoids
         </strong>
         – With the passage of legislation legalizing use of
         <a class="drug drug_general" data-topicid="134930" href="/z/d/drug information/134930.html" rel="external">
          medical cannabis
         </a>
         in many states in the United States and other countries, some researchers have questioned whether cannabis could be a useful treatment for PTSD [
         <a href="#rid53">
          53-55
         </a>
         ]. A role for specific components of cannabis (eg, cannabidiol versus tetrahydrocannabinol) or other cannabinoids (synthetic and naturally occurring) in the treatment of PTSD remains to be determined with further research. A review of open label and observational trials has concluded that cannabis use is associated with worse treatment outcomes in some naturalistic studies and concluded that “known risks of marijuana thus currently outweigh unknown benefits for PTSD” [
         <a href="#rid53">
          53
         </a>
         ]. Further study of cannabinoids and other drugs that enhance the function of endocannabinoids is warranted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Riluzole
         </strong>
         <strong>
          augmentation
         </strong>
         – The glutamatergic modulator
         <a class="drug drug_general" data-topicid="9865" href="/z/d/drug information/9865.html" rel="external">
          riluzole
         </a>
         , has been shown to improve hyperarousal symptoms associated with PTSD but not overall PTSD symptoms. Further study of riluzole and other glutamatergic modulators is warranted [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other antidepressants
         </strong>
         – There is insufficient evidence of effectiveness of antidepressants other than selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors in PTSD, including tricyclic antidepressants, monoamine oxidase inhibitors, serotonin modulators (eg,
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         ), or atypical antidepressants (eg,
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         ) [
         <a href="#rid57">
          57-59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other investigational treatments
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          3,4 methylenedioxymethamphetamine (MDMA
         </strong>
         ) – MDMA (“ecstasy”), a synthetic stimulant with potential for misuse, has been studied clinical trials as a treatment for PTSD and appears to be effective when combined with a very specific, intensive form of psychotherapy [
         <a href="#rid60">
          60,61
         </a>
         ]. In a trial, 104 participants with moderate or severe PTSD (moderate: Clinician Administered PTSD Scale for DSM-5 [CAPS-5] 28 to 34; severe: CAPS-5 ≥35) were randomly assigned to treatment with MDMA-assisted therapy (MDMA-AT) versus placebo with therapy [
         <a href="#rid61">
          61
         </a>
         ]. At 18-week assessment, subjects in the MDMA-AT treatment had a greater reduction in CAPS-5 score, as compared with subjects who received placebo plus therapy (least squares mean change: 23.7 versus 14.8, respectively). At study end, a greater percentage of subjects in the treatment group no longer met criteria for PTSD as compared with the placebo-therapy group (71.2 versus 47.6 percent, respectively). Treatment-emergent adverse effects were more prevalent in the group treated with MDMA-AT; however, no deaths or serious side effects were reported in either group. (See
         <a class="medical medical_review" href="/z/d/html/302.html" rel="external">
          "MDMA (ecstasy) intoxication"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         While research combining MDMA-AT is promising, at present we do not recommend this treatment. MDMA is not yet legally available in the United States for this purpose. Additionally, the intensive form of psychotherapy used in the trial is also not widely available. Furthermore, it is currently unknown if MDMA will be effective for PTSD in combination with other available trauma-focused therapies. Further trials are warranted.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          D-
         </strong>
         <strong>
          cycloserine
         </strong>
         – Use of D-cycloserine to enhance trauma-focused psychotherapy for PTSD has been mixed. The use of D-cycloserine is not recommended at this time.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Propranolol
         </strong>
         <strong>
          and trauma memory reactivation
         </strong>
         – Although research on the combination of
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         and trauma memory reactivation is promising, it is too preliminary to recommend the use of this approach to treatment of PTSD. A randomized clinical trial found that trauma memory reactivation preceded by treatment with propranolol demonstrated an advantage compared with placebo-pretreatment of trauma memory reactivation in reducing PTSD symptoms (as measured by the Clinician Administered PTSD Scale) [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Stellate ganglion blockade
         </strong>
         – Stellate ganglion blockade involves injection of local anesthetic into the stellate ganglion of the sympathetic chain in the neck. Randomized trials have shown mixed results in the treatment of PTSD symptoms [
         <a href="#rid63">
          63,64
         </a>
         ]. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a trial 42 military service members (active-duty or retired) with PTSD were randomly assigned to stellate ganglion blockade using either local anesthetic or sham injection. Participants were reassessed after one week, one month, and three months. Reduction of PTSD symptoms (as measured by the Clinician-Administered PTSD Scale) and self-reported scores for depression and anxiety were similar between groups across time. No differences were seen in complication rates between active and control groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a trial 113 active-duty service members with PTSD symptoms (clinical threshold and subthreshold) were randomly assigned to treatment with two stellate ganglion blockades or sham injections. At eight-week follow-up, the mean change (as measured by the Clinician-Administered PTSD Scale for DSM-5) was greater in the group receiving active treatment than in the treatment receiving sham treatment (mean change -12.2 and -5.8, respectively). Note is made of the mild to moderate level of PTSD symptom severity and the short follow-up time which may limit generalizability.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Further trials investigating the use of stellate ganglion blockade as an adjunctive PTSD treatment are warranted.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4031577511">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initiating treatment
         </strong>
         –
         <strong>
         </strong>
         We prefer to begin treatment for posttraumatic stress disorder (PTSD) as soon as possible after the diagnosis is made. (See
         <a class="local">
          'Initiating treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Goals
         </strong>
         –
         <strong>
         </strong>
         The goals of treatment include maintaining safety of the patient and others, reduce distressing symptoms, reduce avoidant behaviors, diminish anxiety, and improve adaptive and psychosocial functioning, and lessen the risk of relapse. (See
         <a class="local">
          'Establishing treatment goals'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Trauma-focused
         </strong>
         <strong>
          psychotherapy as first line
         </strong>
         – For most adults with PTSD we suggest first-line treatment with a trauma-focused psychotherapy that includes exposure rather than a serotonin reuptake inhibitor (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor [SNRI]) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Trauma-focused psychotherapy as preferred treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SSRIs as alternative first line
         </strong>
         –
         <strong>
         </strong>
         SSRIs are an appropriate alternative to psychotherapy and are preferred in patients with comorbid depression or other anxiety disorder, particularly if their symptoms interfere with psychotherapy. (See
         <a class="local">
          'Serotonin reuptake inhibitors as alternative first-line or adjunctive treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Considerations for specific populations or symptoms
         </strong>
         – We use modified psychotherapeutic approaches that incorporate treatment for PTSD as initial management for individuals with substance use disorders, personality disorders, and moderate-to-severe traumatic brain injury. (See
         <a class="local">
          'Additional considerations for specific populations or symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For individuals with PTSD who experience significant sleep disturbance, typically nightmares, we suggest treatment with
         <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">
          prazosin
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We use prazosin as an augmenting agent with serotonin reuptake inhibitors or in some cases as monotherapy or combined with trauma-focused therapy. (See
         <a class="local">
          'Prominent sleep disturbance or nightmares'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For individuals with PTSD with prominent psychotic symptoms, we suggest treatment with a combination SSRI and second-generation antipsychotic (SGA) medication (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Psychosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of treatment
         </strong>
         – We continue medications that are effective for PTSD for at least six months to one year in order prevent relapse or recurrence. (See
         <a class="local">
          'Duration of treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of suboptimal response
         </strong>
         – Our subsequent choices are as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Individuals with preference for psychotherapy
         </strong>
         –
         <strong>
         </strong>
         For partial response to initial psychotherapy our preference is to augment with another trauma-focused therapy. (See
         <a class="local">
          'Individuals who prefer psychotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For poor response to initial psychotherapy, our preference is to switch to another trauma-focused therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Individuals with preference for medication
         </strong>
         – For individuals with poor response to initial trauma-focused therapy our preference is to discontinue therapy and start pharmacologic management with an SSRI. An SNRI is an acceptable, though less studied, option. (See
         <a class="local">
          'Individuals who prefer medication'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For individuals with poor response to medication management who do not want further psychotherapy, our next choice is to switch to another serotonin reuptake inhibitor (SSRI or SNRI).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          For individuals willing to use combined modalities
         </strong>
         – In our clinical experience, augmentation of psychotherapy with an SSRI (or augmentation of an SSRI with psychotherapy) may be helpful for some. However, clinical trials have provided little direct evidence supporting this option. (See
         <a class="local">
          'Individuals agreeable to combined modalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          For individuals who have not responded to two or more serotonin reuptake inhibitors (SSRI or SNRI)
         </strong>
         – Our preference is to try an SGA. If no clinical benefit is seen after two to three weeks of treatment at the maximal tolerated dose, we gradually discontinue the medication to lessen the risk of side effects. (See
         <a class="local">
          'For individuals refractory to two or more serotonin reuptake inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3630965225">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Barbara Rothbaum, PhD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ursano RJ, Bell C, Eth S, et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry 2004; 161:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisson J, Andrew M. Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2007; :CD003388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coventry PA, Meader N, Melton H, et al. Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis. PLoS Med 2020; 17:e1003262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamblen JL, Norman SB, Sonis JH, et al. A guide to guidelines for the treatment of posttraumatic stress disorder in adults: An update. Psychotherapy (Chic) 2019; 56:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothbaum BO, Davis M. Applying learning principles to the treatment of post-trauma reactions. Ann N Y Acad Sci 2003; 1008:112.
          </a>
         </li>
         <li class="breakAll">
          Institutes of Medicine. Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence, National Academies Press, Washington, DC 2008.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zoellner LA, Roy-Byrne PP, Mavissakalian M, Feeny NC. Doubly Randomized Preference Trial of Prolonged Exposure Versus Sertraline for Treatment of PTSD. Am J Psychiatry 2019; 176:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rauch SAM, Kim HM, Powell C, et al. Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2019; 76:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hetrick SE, Purcell R, Garner B, Parslow R. Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2010; :CD007316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2006; :CD002795.
          </a>
         </li>
         <li class="breakAll">
          Committee on Treatment of Posttraumatic Stress Disorder (Institute of Medicine). Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence, The National Academies Press, Washington, DC 2007.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson J, Baldwin D, Stein DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 2006; 63:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson J, Rothbaum BO, Tucker P, et al. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol 2006; 26:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravindran LN, Stein MB. Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Res 2009; 1293:24.
          </a>
         </li>
         <li class="breakAll">
          Ravindran LN, Stein MB. Anxiety Disorders: Somatic Treatment. In: Kaplan and Sadock Comprehensive Textbook of Psychiatry, Sadock BJ, Sadock VA, Ruiz P (Eds), Lippincott Williams and Wilkins, Philadelphia 2009. p.1906.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection. J Clin Psychiatry 2008; 69:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harpaz-Rotem I, Rosenheck RA, Mohamed S, Desai RA. Pharmacologic treatment of posttraumatic stress disorder among privately insured Americans. Psychiatr Serv 2008; 59:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodnight JRM, Ragsdale KA, Rauch SAM, Rothbaum BO. Psychotherapy for PTSD: An evidence-based guide to a theranostic approach to treatment. Prog Neuropsychopharmacol Biol Psychiatry 2019; 88:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruglass LM, Lopez-Castro T, Papini S, et al. Concurrent Treatment with Prolonged Exposure for Co-Occurring Full or Subthreshold Posttraumatic Stress Disorder and Substance Use Disorders: A Randomized Clinical Trial. Psychother Psychosom 2017; 86:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norman SB, Trim R, Haller M, et al. Efficacy of Integrated Exposure Therapy vs Integrated Coping Skills Therapy for Comorbid Posttraumatic Stress Disorder and Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2019; 76:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harned MS, Korslund KE, Foa EB, Linehan MM. Treating PTSD in suicidal and self-injuring women with borderline personality disorder: development and preliminary evaluation of a Dialectical Behavior Therapy Prolonged Exposure Protocol. Behav Res Ther 2012; 50:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jak AJ, Jurick S, Crocker LD, et al. SMART-CPT for veterans with comorbid post-traumatic stress disorder and history of traumatic brain injury: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2019; 90:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raskind MA, Peskind ER, Chow B, et al. Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. N Engl J Med 2018; 378:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khachatryan D, Groll D, Booij L, et al. Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials. Gen Hosp Psychiatry 2016; 39:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raskind MA, Peterson K, Williams T, et al. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry 2013; 170:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raskind MA, Millard SP, Petrie EC, et al. Higher Pretreatment Blood Pressure Is Associated With Greater Posttraumatic Stress Disorder Symptom Reduction in Soldiers Treated With Prazosin. Biol Psychiatry 2016; 80:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Berg DP, de Bont PA, van der Vleugel BM, et al. Prolonged exposure vs eye movement desensitization and reprocessing vs waiting list for posttraumatic stress disorder in patients with a psychotic disorder: a randomized clinical trial. JAMA Psychiatry 2015; 72:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villarreal G, Hamner MB, Cañive JM, et al. Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. Am J Psychiatry 2016; 173:1205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krystal JH, Rosenheck RA, Cramer JA, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA 2011; 306:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carey P, Suliman S, Ganesan K, et al. Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Hum Psychopharmacol 2012; 27:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002; 159:1777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothbaum BO, Killeen TK, Davidson JR, et al. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry 2008; 69:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padala PR, Madison J, Monnahan M, et al. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol 2006; 21:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reich DB, Winternitz S, Hennen J, et al. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry 2004; 65:1601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson J, Pearlstein T, Londborg P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001; 158:1974.
          </a>
         </li>
         <li class="breakAll">
          Cahill SP, Rothbaum BO, Resick PA, Follette VM. Cognitive behavior therapy for treatment of PTSD in adults. In: Effective Treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies, 2nd ed, Foa EB, Keane TM, Friedman MJ, Cohe J (Eds), Guilford Press, New York 2008.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber M, Schumacher S, Hannig W, et al. Long-term outcomes of psychological treatment for posttraumatic stress disorder: a systematic review and meta-analysis. Psychol Med 2021; 51:1420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunlop BW, Kaye JL, Youngner C, Rothbaum B. Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP). Behav Sci (Basel) 2014; 4:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneier FR, Neria Y, Pavlicova M, et al. Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial. Am J Psychiatry 2012; 169:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothbaum BO, Cahill SP, Foa EB, et al. Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Trauma Stress 2006; 19:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon NM, Connor KM, Lang AJ, et al. Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry 2008; 69:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothbaum BO, Price M, Jovanovic T, et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry 2014; 171:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steenen SA, van Wijk AJ, van der Heijden GJ, et al. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J Psychopharmacol 2016; 30:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis LL, Davidson JR, Ward LC, et al. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol 2008; 28:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamner MB, Faldowski RA, Robert S, et al. A preliminary controlled trial of divalproex in posttraumatic stress disorder. Ann Clin Psychiatry 2009; 21:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson JR, Brady K, Mellman TA, et al. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 2007; 27:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tucker P, Trautman RP, Wyatt DB, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol 2007; 27:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeh MS, Mari JJ, Costa MC, et al. A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neurosci Ther 2011; 17:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2014; 71:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feder A, Costi S, Rutter SB, et al. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry 2021; 178:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philipp-Muller AE, Stephenson CJ, Moghimi E, et al. Combining Ketamine and Psychotherapy for the Treatment of Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry 2023; 84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steenkamp MM, Blessing EM, Galatzer-Levy IR, et al. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review. Depress Anxiety 2017; 34:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shishko I, Oliveira R, Moore TA, Almeida K. A review of medical marijuana for the treatment of posttraumatic stress disorder: Real symptom re-leaf or just high hopes? Ment Health Clin 2018; 8:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turna J, Patterson B, Van Ameringen M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depress Anxiety 2017; 34:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spangler PT, West JC, Dempsey CL, et al. Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms. J Clin Psychiatry 2020; 81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein MB, Rothbaum BO. 175 Years of Progress in PTSD Therapeutics: Learning From the Past. Am J Psychiatry 2018; 175:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charney ME, Hellberg SN, Bui E, Simon NM. Evidenced-Based Treatment of Posttraumatic Stress Disorder: An Updated Review of Validated Psychotherapeutic and Pharmacological Approaches. Harv Rev Psychiatry 2018; 26:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis LL, Pilkinton P, Lin C, et al. A Randomized, Placebo-Controlled Trial of Mirtazapine for the Treatment of Posttraumatic Stress Disorder in Veterans. J Clin Psychiatry 2020; 81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 2021; 27:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell JM, Ot'alora G M, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 2023; 29:2473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunet A, Saumier D, Liu A, et al. Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial. Am J Psychiatry 2018; 175:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanling SR, Hickey A, Lesnik I, et al. Stellate Ganglion Block for the Treatment of Posttraumatic Stress Disorder: A Randomized, Double-Blind, Controlled Trial. Reg Anesth Pain Med 2016; 41:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rae Olmsted KL, Bartoszek M, Mulvaney S, et al. Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder Symptoms: A Randomized Clinical Trial. JAMA Psychiatry 2020; 77:130.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 117909 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15617511" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17636720" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Psychological treatment of post-traumatic stress disorder (PTSD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32813696" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31282712" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A guide to guidelines for the treatment of posttraumatic stress disorder in adults: An update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14998877" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Applying learning principles to the treatment of post-trauma reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14998877" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Applying learning principles to the treatment of post-trauma reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30336702" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Doubly Randomized Preference Trial of Prolonged Exposure Versus Sertraline for Treatment of PTSD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30516797" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20614457" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16437445" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pharmacotherapy for post traumatic stress disorder (PTSD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16437445" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pharmacotherapy for post traumatic stress disorder (PTSD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17015818" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16702890" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19332035" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pharmacotherapy of PTSD: premises, principles, and priorities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19332035" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Pharmacotherapy of PTSD: premises, principles, and priorities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18588361" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18832505" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pharmacologic treatment of posttraumatic stress disorder among privately insured Americans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29786514" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Psychotherapy for PTSD: An evidence-based guide to a theranostic approach to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28490022" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Concurrent Treatment with Prolonged Exposure for Co-Occurring Full or Subthreshold Posttraumatic Stress Disorder and Substance Use Disorders: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31017639" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Efficacy of Integrated Exposure Therapy vs Integrated Coping Skills Therapy for Comorbid Posttraumatic Stress Disorder and Alcohol Use Disorder: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22503959" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Treating PTSD in suicidal and self-injuring women with borderline personality disorder: development and preliminary evaluation of a Dialectical Behavior Therapy Prolonged Exposure Protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30554135" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : SMART-CPT for veterans with comorbid post-traumatic stress disorder and history of traumatic brain injury: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29414272" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26644317" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23846759" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27320368" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Higher Pretreatment Blood Pressure Is Associated With Greater Posttraumatic Stress Disorder Symptom Reduction in Soldiers Treated With Prazosin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25607833" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Prolonged exposure vs eye movement desensitization and reprocessing vs waiting list for posttraumatic stress disorder in patients with a psychotic disorder: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27418378" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21813427" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22730105" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12359687" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18278987" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16877898" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15641864" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11729012" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11729012" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34176532" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Long-term outcomes of psychological treatment for posttraumatic stress disorder: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25494488" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21908494" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17075912" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18348595" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24743802" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26487439" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18204347" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19439158" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A preliminary controlled trial of divalproex in posttraumatic stress disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17224720" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17335317" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18004136" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21554564" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24740528" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33397139" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36752752" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Combining Ketamine and Psychotherapy for the Treatment of Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28245077" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29955551" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A review of medical marijuana for the treatment of posttraumatic stress disorder: Real symptom re-leaf or just high hopes?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28636769" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33113596" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29869547" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : 175 Years of Progress in PTSD Therapeutics: Learning From the Past.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29734225" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Evidenced-Based Treatment of Posttraumatic Stress Disorder: An Updated Review of Validated Psychotherapeutic and Pharmacological Approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33084254" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A Randomized, Placebo-Controlled Trial of Mirtazapine for the Treatment of Posttraumatic Stress Disorder in Veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33972795" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37709999" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29325446" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27187898" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Stellate Ganglion Block for the Treatment of Posttraumatic Stress Disorder: A Randomized, Double-Blind, Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31693083" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder Symptoms: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
